Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant? [0.03%]
所有新诊断的未经治急性髓系白血病患者都需要诱导化疗后再进行移植吗？
E Rodríguez-Arbolí,R P Gale
E Rodríguez-Arbolí
Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus [0.03%]
国际专家共识：定义造血干细胞移植后骨髓纤维化的缓解期标准
Rachel B Salit,Elizabeth O Hexner,Nico Gagelmann et al.
Rachel B Salit et al.
Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis [0.03%]
蒽环类药物诱导缓解治疗后急性髓系白血病患者心力衰竭的系统评价和meta分析
Jesse Geels,Anna van Rhenen,Patrycja Gradowska et al.
Jesse Geels et al.
Patients with acute myeloid leukemia (AML) are at increased risk of cardiovascular disease, particularly heart failure. Anthracyclines are integral to remission induction therapy in patients eligible for intensive treatment and well-known f...
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations [0.03%]
UBA1 M41和复发的功能性非M41变异体的VEXAS致病特征差异
Maki Sakuma,Amy K Wang,Samuel J Magaziner et al.
Maki Sakuma et al.
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe inflammatory and hematologic disease caused by somatic mutations in UBA1. Canonical pathogenic mutations at UBA1 p.Met41 (M41) lead to the loss of the cyt...
Epigenetic dysregulation in Erdheim-Chester disease: perspectives from tissue and blood [0.03%]
Erdos-Chester病的表观遗传调控异常：来自组织和血液的研究观点
Refael Meyuchas,Ofer Shpilberg,Oshrat Hershkovitz-Rokah
Refael Meyuchas
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment [0.03%]
基于儿童和青少年急性髓系白血病诊断与风险评估的全基因组及转录组测序临床应用经验
Rebecca K Voss,Victor B Pastor Loyola,Maria F Cardenas et al.
Rebecca K Voss et al.
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS...
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma [0.03%]
不同的分子途径驱动单型上皮浸润性和肠病相关性肠T细胞淋巴瘤
David Vallois,Edoardo Missiaglia,Luis Veloza et al.
David Vallois et al.
Enteropathy-associated intestinal T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) have distinctive clinical context, morphology, and immunophenotype. To characterize their genetic and molecular spec...
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial [0.03%]
去甲磺酸治疗急性髓系白血病失败后的继发耐药的遗传和表观遗传改变：DECINDER 随机II期试验的结果
Inga Hund,Maria Elena Hess,Geoffroy Andrieux et al.
Inga Hund et al.
Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia [0.03%]
氨鲁米特联合阿糖胞苷通过S100A6-Akt途径诱导KMT2A::AFF1阳性急性淋巴细胞白血病凋亡的联合治疗
Hayato Tamai,Koichi Miyake,Noriko Miyake et al.
Hayato Tamai et al.
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib [0.03%]
固定剂量的维奈克拉与布鲁顿酪氨酸激酶抑制剂联合治疗慢性淋巴细胞白血病：依布替尼和阿卡替尼之间的差异分析
Alessandra Tedeschi,Anna Maria Frustaci,Pierantonio Menna et al.
Alessandra Tedeschi et al.